- Home
- TNMG vs AGEN Comparison
TNMG vs AGEN Comparison
Compare TNMG & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNMG
- AGEN
- Stock Information
- Founded
- TNMG 2023
- AGEN 1994
- Country
- TNMG Japan
- AGEN United States
- Employees
- TNMG N/A
- AGEN N/A
- Industry
- TNMG
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TNMG
- AGEN Health Care
- Exchange
- TNMG NYSE
- AGEN Nasdaq
- Market Cap
- TNMG 93.7M
- AGEN 96.2M
- IPO Year
- TNMG N/A
- AGEN 2000
- Fundamental
- Price
- TNMG $0.77
- AGEN $1.47
- Analyst Decision
- TNMG
- AGEN Buy
- Analyst Count
- TNMG 0
- AGEN 4
- Target Price
- TNMG N/A
- AGEN $8.00
- AVG Volume (30 Days)
- TNMG 49.4K
- AGEN 488.3K
- Earning Date
- TNMG 01-01-0001
- AGEN 03-11-2025
- Dividend Yield
- TNMG N/A
- AGEN N/A
- EPS Growth
- TNMG N/A
- AGEN N/A
- EPS
- TNMG N/A
- AGEN N/A
- Revenue
- TNMG N/A
- AGEN $103,463,000.00
- Revenue This Year
- TNMG N/A
- AGEN $32.21
- Revenue Next Year
- TNMG N/A
- AGEN N/A
- P/E Ratio
- TNMG N/A
- AGEN N/A
- Revenue Growth
- TNMG N/A
- AGEN N/A
- 52 Week Low
- TNMG $0.70
- AGEN $1.55
- 52 Week High
- TNMG $34.08
- AGEN $19.69
- Technical
- Relative Strength Index (RSI)
- TNMG N/A
- AGEN 23.91
- Support Level
- TNMG N/A
- AGEN $1.55
- Resistance Level
- TNMG N/A
- AGEN $1.77
- Average True Range (ATR)
- TNMG 0.00
- AGEN 0.16
- MACD
- TNMG 0.00
- AGEN 0.02
- Stochastic Oscillator
- TNMG 0.00
- AGEN 6.76
About TNMG TNL MEDIAGENE
TNL Mediagene is a comprehensive media and data platform providing news and commentary on current events, business, technology, lifestyle and sports.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).